A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Local Institution - 0015, Beijing

Local Institution - 0001, Beijing

Local Institution - 0011, Harbin

Local Institution - 0016, Shanghai

Local Institution - 0004, Tianjin

Local Institution - 0013, Hangzhou

Local Institution - 0021, Wuhan

Local Institution, Zhengzhou

Local Institution, Guangzhou

Local Institution - 0012, Guangzhou

Local Institution - 0018, Chengdu

Local Institution - 0020, Xi'an